Bristol-Myers Squibb Company BRM.DE · Stock Open Bristol-Myers Squibb Company in new tab
Bristol-Myers Squibb Company Analysis (BRM.DE)
Is Bristol-Myers Squibb Company a good investment? Bristol-Myers Squibb Company (BRM.DE) is currently trading at 55.37 EUR.
In terms of valuation, the stock trades at a P/E ratio of 17.11. This valuation is generally in line with the broader market.
Earnings Schedule: Bristol-Myers Squibb Company is expected to release its next earnings report on July 30, 2026.
For income investors, Bristol-Myers Squibb Company pays a dividend yield of 4.21%. With a payout ratio of 70%, the dividend appears sustainable.
Investor FAQ
Does Bristol-Myers Squibb Company pay a dividend?
Yes, it pays an annual dividend of 2.51 EUR (4.21% yield).
What asset class is Bristol-Myers Squibb Company?
Bristol-Myers Squibb Company is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be July 30, 2026. The company currently has a trailing EPS of 3.13.
Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
| Year | Total Dividends |
|---|---|
| ▸2027 |
1.11 EUR
|
| May 3, 2027 (estimated) | 0.5538 |
| Feb. 1, 2027 (estimated) | 0.5538 |
| ▸2026 |
2.21 EUR
|
| Nov. 2, 2026 (estimated) | 0.5450 |
| Aug. 3, 2026 | 0.5538 |
| May 1, 2026 | 0.5538 |
| Feb. 2, 2026 | 0.5538 |
| ▸2025 |
2.18 EUR
|
| Nov. 3, 2025 | 0.5450 |
| Aug. 1, 2025 | 0.5450 |
| May 1, 2025 | 0.5450 |
| Feb. 3, 2025 | 0.5450 |
| ▸2024 |
2.11 EUR
|
| Nov. 1, 2024 | 0.5275 |
| Aug. 1, 2024 | 0.5275 |
| May 1, 2024 | 0.5275 |
| Jan. 4, 2024 | 0.5275 |
| ▸2023 |
2.00 EUR
|
| Oct. 5, 2023 | 0.5011 |
| July 6, 2023 | 0.5011 |
| April 6, 2023 | 0.5011 |
| Feb. 1, 2023 | 0.5011 |
| ▸2022 |
1.90 EUR
|
| Nov. 1, 2022 | 0.4747 |
| June 30, 2022 | 0.4747 |
| March 31, 2022 | 0.4747 |
| Jan. 6, 2022 | 0.4747 |
| ▸2021 |
1.29 EUR
|
| Sept. 30, 2021 | 0.4308 |
| July 1, 2021 | 0.4308 |
| March 31, 2021 | 0.4308 |
| ▸2020 |
2.50 EUR
|
| Dec. 31, 2020 | 0.4900 |
| Dec. 30, 2020 | 0.4308 |
| Oct. 1, 2020 | 0.3956 |
| Aug. 3, 2020 | 0.3956 |
| May 1, 2020 | 0.3956 |
| Feb. 3, 2020 | 0.3956 |
| ▸2019 |
1.85 EUR
|
| Nov. 1, 2019 | 0.4100 |
| Oct. 2, 2019 | 0.3604 |
| Aug. 1, 2019 | 0.3604 |
| May 1, 2019 | 0.3604 |
| Feb. 1, 2019 | 0.3604 |
| ▸2018 |
1.41 EUR
|
| Nov. 1, 2018 | 0.3516 |
| Aug. 1, 2018 | 0.3516 |
| May 1, 2018 | 0.3516 |
| Feb. 1, 2018 | 0.3516 |
| ▸2017 |
1.37 EUR
|
| Nov. 1, 2017 | 0.3428 |
| Aug. 1, 2017 | 0.3428 |
| May 1, 2017 | 0.3428 |
| Feb. 1, 2017 | 0.3428 |
| ▸2016 |
1.34 EUR
|
| Nov. 1, 2016 | 0.3341 |
| Aug. 1, 2016 | 0.3341 |
| May 2, 2016 | 0.3341 |
| Feb. 1, 2016 | 0.3341 |
| ▸2015 |
1.30 EUR
|
| Nov. 2, 2015 | 0.3253 |
| July 1, 2015 | 0.3253 |
| April 1, 2015 | 0.3253 |
| Feb. 2, 2015 | 0.3253 |
| ▸2014 |
1.27 EUR
|
| Oct. 1, 2014 | 0.3165 |
| July 1, 2014 | 0.3165 |
| May 1, 2014 | 0.3165 |
| Feb. 3, 2014 | 0.3165 |
| ▸2013 |
1.23 EUR
|
| Nov. 1, 2013 | 0.3077 |
| Aug. 1, 2013 | 0.3077 |
| May 1, 2013 | 0.3077 |
| Feb. 1, 2013 | 0.3077 |
| ▸2012 |
1.54 EUR
|
| Nov. 1, 2012 | 0.3400 |
| Oct. 2, 2012 | 0.2989 |
| Aug. 1, 2012 | 0.2989 |
| May 1, 2012 | 0.2989 |
| Jan. 4, 2012 | 0.2989 |
| ▸2011 |
1.16 EUR
|
| Oct. 6, 2011 | 0.2901 |
| June 29, 2011 | 0.2901 |
| March 30, 2011 | 0.2901 |
| Jan. 5, 2011 | 0.2901 |
| ▸2010 |
0.84 EUR
|
| Sept. 29, 2010 | 0.2813 |
| June 30, 2010 | 0.2813 |
| March 30, 2010 | 0.2813 |
| ▸2009 |
1.10 EUR
|
| Dec. 30, 2009 | 0.2813 |
| Sept. 30, 2009 | 0.2725 |
| July 1, 2009 | 0.2725 |
| April 1, 2009 | 0.2725 |
| ▸2008 |
1.36 EUR
|
| Dec. 30, 2008 | 0.2725 |
| Oct. 1, 2008 | 0.2725 |
| July 2, 2008 | 0.2725 |
| April 2, 2008 | 0.2725 |
| Jan. 2, 2008 | 0.2725 |
| ▸2007 |
0.98 EUR
|
| Oct. 3, 2007 | 0.2461 |
| July 3, 2007 | 0.2461 |
| April 3, 2007 | 0.2461 |
| Jan. 3, 2007 | 0.2461 |
| ▸2006 |
0.98 EUR
|
| Oct. 4, 2006 | 0.2461 |
| July 5, 2006 | 0.2461 |
| April 5, 2006 | 0.2461 |
| Jan. 4, 2006 | 0.2461 |
| ▸2005 |
0.98 EUR
|
| Oct. 5, 2005 | 0.2461 |
| June 29, 2005 | 0.2461 |
| March 30, 2005 | 0.2461 |
| Jan. 5, 2005 | 0.2461 |
| ▸2004 |
0.74 EUR
|
| Sept. 29, 2004 | 0.2461 |
| June 30, 2004 | 0.2461 |
| March 31, 2004 | 0.2461 |
| ▸2003 |
0.98 EUR
|
| Dec. 30, 2003 | 0.2461 |
| Oct. 1, 2003 | 0.2461 |
| July 1, 2003 | 0.2461 |
| April 2, 2003 | 0.2461 |
| ▸2002 |
1.23 EUR
|
| Dec. 31, 2002 | 0.2461 |
| Oct. 2, 2002 | 0.2461 |
| July 2, 2002 | 0.2461 |
| April 3, 2002 | 0.2461 |
| Jan. 2, 2002 | 0.2461 |
| ▸2001 |
0.97 EUR
|
| Oct. 3, 2001 | 0.2418 |
| July 3, 2001 | 0.2418 |
| April 4, 2001 | 0.2418 |
| Jan. 3, 2001 | 0.2418 |
| ▸2000 |
0.86 EUR
|
| Oct. 4, 2000 | 0.2154 |
| July 5, 2000 | 0.2154 |
| April 5, 2000 | 0.2154 |
| Jan. 5, 2000 | 0.2154 |
| ▸1999 |
0.38 EUR
|
| Sept. 29, 1999 | 0.1890 |
| June 30, 1999 | 0.1890 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Bristol-Myers Squibb Company | Aug 03, 2026 | Upcoming | 0.553833 EUR |
| Bristol-Myers Squibb Company | May 01, 2026 | Paid | 0.553833 EUR |
| Bristol-Myers Squibb Company | Feb 02, 2026 | Paid | 0.553833 EUR |
| Bristol-Myers Squibb Company | Nov 03, 2025 | Paid | 0.545042 EUR |
Community Discussion